SynthesisInternational ophthalmology2025
SGLT2 inhibitors for delaying diabetic retinopathy: a systematic review and meta-analysis.
Synthesis in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sodium-glucose cotransporter-2 inhibitors and risk of diabetic retinopathy in type 2 diabetes: a network meta-analysis of randomised clinical trials.International journal of clinical pharmacy · 2026Pooled it
- Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study.Diabetes, obesity & metabolism · 2026Article
- Retinal Outcomes in Diabetes: Antihyperglycemic Therapy, EWDR, and Perioperative Considerations.Biomedicines · 2026Review
- The association between SGLT2 inhibitor use and diabetic peripheral neuropathy in type 2 diabetes: a cross-sectional study.Frontiers in endocrinology · 2026Article
- Predicting sight-threatening diabetic retinopathy using the combination of serum cystatin C and indirect bilirubin.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic retinopathy (DR) is a leading cause of vision loss among individuals with type 2 diabetes mellitus (T2DM), necessitating effective interventions to prevent disease progression. This systematic review was conducted to evaluate the potential role of sodium-glucose co-transporter 2 (SGLT2) inhibitors as predictive factors of DR.
methodsA comprehensive search of PubMed, Embase, Cochrane Library, Web of Science, and Scopus databases was conducted up to December 8, 2024, following PRISMA guidelines. Studies reporting DR outcomes among SGLT2 inhibitor users compared to other glucose-lowering therapies were included.
resultsSixteen cohort studies involving over 400,000 participants were included. SGLT2 inhibitors significantly reduced the risk of DR progression compared to other treatments (HR: 0.75; 95% CI: 0.67-0.85; p < 0.001), despite substantial heterogeneity (I
conclusionsSGLT2 inhibitors significantly reduce the progression and incidence of diabetic retinopathy, underscoring their potential as a key component in comprehensive diabetes management. Further high-quality, long-term randomized trials are warranted to confirm these findings and elucidate underlying mechanisms.
Indexed as
Identifiers
41042286What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.